The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 96, Issue 2, Pages 241-250
Publisher
Wiley
Online
2020-11-13
DOI
10.1002/ajh.26047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
- (2019) Koji Sasaki et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2018) Jerald P. Radich et al. Journal of the National Comprehensive Cancer Network
- Machine-learning-based patient-specific prediction models for knee osteoarthritis
- (2018) Afshin Jamshidi et al. Nature Reviews Rheumatology
- Machine-learning analysis outperforms conventional statistical models and CT classification systems in predicting 6-month outcomes in pediatric patients sustaining traumatic brain injury
- (2018) Andrew T. Hale et al. Neurosurgical Focus
- Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes
- (2017) Daniel Shu Wei Ting et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dermatologist-level classification of skin cancer with deep neural networks
- (2017) Andre Esteva et al. NATURE
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients
- (2016) Pratibha S. Binder et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
- (2016) Torsten Dahlén et al. ANNALS OF INTERNAL MEDICINE
- Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
- (2016) Varun Gulshan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
- (2015) S. Saussele et al. BLOOD
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
- (2015) M Pfirrmann et al. LEUKEMIA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
- (2015) Preetesh Jain et al. Lancet Haematology
- Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma
- (2013) Amit G Singal et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Gradient boosting machines, a tutorial
- (2013) Alexey Natekin et al. Frontiers in Neurorobotics
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
- (2011) J. Hasford et al. BLOOD
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
- (2011) E. Jabbour et al. BLOOD
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started